The Invisible Burden of a Visible Disease: Exploring Psychosocial Burden and Quality of Life Impairment in Vitiligo
SKIN The Journal of Cutaneous Medicine · 10.03.2026 · 10 (2) · s751
DOI: 10.25251/m6k57139 ↗Kurz gefasst
Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.03.2026. Verfasst von Pearl Craig und 15 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Vitiligo is a chronic autoimmune disease characterized by patches of depigmentation on the skin or hair, or both, with an estimated global prevalence ranging from 0.4 to 2%. Beyond its visible manifestations, vitiligo is associated with emotional distress, social challenges, and impairments in work productivity, daily activities, and overall health-related quality of life. However, the extent of this burden varies substantially and may be moderated by multiple factors, such as lesion visibility, internalized social stigma, and learned coping mechanisms. This study examined how psychosocial burden varies across these factors among adults with vitiligo in the United States (US) and Europe.
Methods
An online cross-sectional survey was administered to adults with vitiligo in the US and Europe (United Kingdom, Germany, France, Italy, and Spain). Patient-reported vitiligo disease burden was assessed using the Vitiligo Impact Patient Scale (VIPS), a 29-item validated instrument measuring the psychosocial burden and quality of life of vitiligo across four domains: psychosocial functioning, social functioning, relationship functioning, and treatment burden7. VIPS scores range from 0 to 95 with higher scores equating to a greater burden. VIPS scores were stratified by patient-reported vitiligo severity on face (none, mild, moderate, severe, very severe), severity on body (none, mild, moderate, severe, very severe), years since initial diagnosis (≤5, >5 years), and severity of vitiligo-related stigma (mild, moderate to severe). Stigma was measured using the Patient Unique Stigmatization Holistic Tool in Dermatology (PUSH-D), a 17-item validated instrument assessing felt stigma and enacted stigma. Significant associations were evaluated using Chi-squared tests (p5 years; 15.4 [19.8]; p = 0.002). Respondents reporting moderate to severe stigma (PUSH-D score ≥14) also reported significantly higher VIPS scores (51.4 [22.4]) than those with mild internalized stigma (PUSH-D score
Zitieren
APA
Craig, P., Hwang, S., Maculaitis, M., Way, N., Kurosky, S. K., Paudel, N., Sadrarhami, M., Dumas, A., Adiri, R., King-Concialdi, K., McCaig, E., Gauthier, G., Aftab, Y., Canosa, J. M., Eleftheriadou, V., & Ezzedine, K. (2026). The Invisible Burden of a Visible Disease: Exploring Psychosocial Burden and Quality of Life Impairment in Vitiligo. SKIN The Journal of Cutaneous Medicine, 10(2), s751. https://doi.org/10.25251/m6k57139
Vancouver
Craig P, Hwang S, Maculaitis M, Way N, Kurosky SK, Paudel N, et al. The Invisible Burden of a Visible Disease: Exploring Psychosocial Burden and Quality of Life Impairment in Vitiligo. SKIN The Journal of Cutaneous Medicine. 2026;10(2):s751. doi:10.25251/m6k57139
BibTeX
@article{Craig2026,
author = {Craig, Pearl and Hwang, Soohyun and Maculaitis, Martine and Way, Nathaniel and Kurosky, Samantha K. and Paudel, Neelanzana and Sadrarhami, Mojgan and Dumas, Anna and Adiri, Roni and King-Concialdi, Kristen and McCaig, Elizabeth and Gauthier, Genevieve and Aftab, Yousaf and Canosa, Juliana M. and Eleftheriadou, Viktoria and Ezzedine, Khaled},
title = {The Invisible Burden of a Visible Disease: Exploring Psychosocial Burden and Quality of Life Impairment in Vitiligo},
journal = {SKIN The Journal of Cutaneous Medicine},
year = {2026},
volume = {10},
number = {2},
pages = {s751},
doi = {10.25251/m6k57139}
}
EUVIMED